NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment

Company Overview - NeuroOne Medical Technologies Corporation (NMTC) received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain [1][7] - The OneRF platform utilizes proprietary multi-contact RF probe technology for precise localization and tailored ablation under temperature-controlled conditions, enhancing patient safety and reducing procedural time [2][9] - NMTC plans a limited commercial launch of the OneRF system in the fourth quarter of 2025, targeting revenue growth opportunities [1][7] Market Potential - The FDA clearance is a significant growth catalyst for NMTC, expanding its OneRF platform into the large pain management market, which is expected to create near-term revenue potential [4] - The global trigeminal neuralgia treatment market was valued at $255.09 million in 2024 and is projected to reach $392.34 million by 2033, with a CAGR of 4.9% [11] - The increasing incidence of trigeminal neuralgia and the growing geriatric population are expected to drive market expansion [12] Stock Performance - Following the FDA clearance announcement, NMTC's shares gained 7% in pre-market trading, with a year-to-date increase of 0.5% compared to the industry's 1% growth [3] - NMTC currently has a market capitalization of $40.9 million [6]